Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895145 | 0.76 | GRIN1 (0.39) | ATMPOLBSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1719023 | 0.74 | ATM (0.42) | ATMMAPTPOLBHPGDMEN1 | |
| SCHEMBL4667034 | 0.73 | POLB (0.50) | ATMMAPTPOLBMEN1KMT2A | |
| SCHEMBL9187670 | 0.72 | DRD2 (0.55) | MAPTMTNR1AMTNR1B | |
| SCHEMBL9189347 | 0.69 | DRD2 (0.57) | MAPTMTNR1AMTNR1B | |
| SCHEMBL9189565 | 0.69 | MTNR1A (0.42) | MAPTMTNR1AMTNR1B | |
| SCHEMBL3756960 | 0.68 | CA1 (0.54) | KMT2ASMN1; SMN2MTNR1AMTNR1BNPC1 | |
| SCHEMBL1993959 | 0.68 | LMNA (0.49) | POLB | |
| SCHEMBL8314550 | 0.67 | DRD2 (0.60) | — | |
| SCHEMBL12567258 | 0.67 | RAB9A (0.42) | ATMMAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298138-A1 | Aminoazoline and Urea Derivatives for Combating Animal Pests | BASF SE (DE) | 2010-11-25 | — | — | US | disclosed |
| EP-2120576-A2 | AMINOAZOLINE AND UREA DERIVATIVES FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008145615-A2 | AMINOAZOLINE AND UREA DERIVATIVES FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298138-A1 | Aminoazoline and Urea Derivatives for Combating Animal Pests | AADAT, INMT, SLC14A1 | ATM 164/4885MAPT 304/4885POLB 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.